Welcome to our dedicated page for Ernexa news (Ticker: ERNA), a resource for investors and traders seeking the latest updates and insights on Ernexa stock.
Ernexa Therapeutics Inc. (NASDAQ: ERNA) generates news primarily around its development of cell therapies for advanced cancer and autoimmune disease. Company announcements emphasize progress with its iPSC-derived iMSC platform, preclinical data readouts, regulatory interactions, and collaborations that support the transition from research to clinical testing.
A central theme in Ernexa’s news flow is the advancement of its lead program, ERNA-101, for ovarian cancer, including platinum-resistant ovarian cancer. Updates have covered positive preclinical data demonstrating immune activation and survival benefits in ovarian cancer models, presentations at major scientific meetings such as the American Society of Hematology Annual Meeting, and participation in conferences focused on cell and gene therapies and iPSC-based drug development.
Investors and observers can also expect news on Ernexa’s broader platform and pipeline, including ERNA-201 for autoimmune and inflammatory diseases. Releases have highlighted how the company’s engineered iMSCs are designed to deliver cytokines directly into tumors or inflamed tissues, reprogram tumor microenvironments, and potentially address unmet medical needs in oncology and autoimmune indications.
Additional news topics include regulatory milestones like the successful completion of a Pre-IND meeting with the U.S. Food and Drug Administration for ERNA-101, operational updates on technology transfer and manufacturing readiness, and strategic partnerships such as the collaboration with Cellipont Bioservices for engineering, differentiation, and production activities. Financial updates, including quarterly performance and operating discipline, also appear in Ernexa’s disclosures.
For readers tracking ERNA, this news page offers a focused view of scientific presentations, preclinical results, regulatory progress, manufacturing partnerships, and corporate developments that shape the company’s efforts to bring its iMSC-based therapies toward first-in-human trials and beyond.
Eterna Therapeutics Inc. (Nasdaq: ERNA) has entered into a sponsored research agreement with Dr. Michael Andreeff from MD Anderson Cancer Center to evaluate its gene-edited iPS cell therapeutic candidates. The research aims to enhance T-cell immunity and promote hematopoietic regeneration, potentially accelerating treatments for acute myeloid leukemia and solid tumors. Eterna's mRNA-based cell therapies are noted for their manufacturing consistency. CEO Matt Angel expressed enthusiasm for advancing cancer treatment through this agreement, which is a critical component of Eterna's cancer therapy pipeline.
Eterna Therapeutics Inc. (Nasdaq: ERNA) announced that Dr. Matt Angel, the Interim CEO, will present at the iPSC-Derived Immunotherapies Congress on October 18-19, 2022, in Boston. The presentation, titled "Avoiding Vector Integration Using mRNA Vectorization of Reprogramming and Gene Editing Proteins," is scheduled for October 18, 2022, at 3:10 p.m. ET at the Hilton Boston Back Bay Hotel. Eterna focuses on advanced cell engineering technology to develop new medicines and holds over 100 patents related to cell engineering.
Eterna Therapeutics Inc. (Nasdaq: ERNA) announced an option agreement with Exacis Biotherapeutics to negotiate an exclusive, worldwide license for developing up to four iNK and/or iT cell programs targeting hematologic malignancies and solid tumors. This partnership highlights Exacis' advanced non-viral cell engineering technology, aimed at creating next-generation therapies without the risks associated with viral integration. The agreement must be finalized by December 31, 2022. Eterna has also completed its name change from Brooklyn ImmunoTherapeutics.